Uterine adenosarcoma: Clinical significance of histological classification and SNP array analysis

Carine Ngo, Sophie Cotteret, Imène Deneche, Maria Kfoury, Randa Chehab, Alicia Tran-Dien, Julien Vibert, Alexandra Leary, Sébastien Gouy, Amandine Maulard, Philippe Morice, Jean Yves Scoazec, Patricia Pautier, Catherine Genestie

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    Résumé

    Mullerian adenosarcoma is a rare malignant biphasic tumor. The mesenchymal component may be low or high grade, with or without sarcomatous overgrowth (SO). Little is known about the molecular heterogeneity of these tumors. In this study, we aim to reclassify a large retrospective monocentric cohort of uterine adenosarcomas according to tumor grade and SO, to evaluate the clinical significance of pathological classification and to correlate with copy-number variations inferred from single nucleotide polymorphism array. Of the 67 uterine adenosarcomas, 18 (26.9%) were low grade without SO, 7 (10.4%) low grade with SO, 8 (11.9%) high grade without SO and 34 (50.7%) high grade with SO. SO, necrosis and RMS were more frequent in high grade than low grade adenosarcomas (p < 0.001). Low-rank test showed that recurrence-free survival was significantly shortened in high grade than low grade adenosarcomas (p = 0.035) and SO was associated with shortened overall and recurrence-free survival (p = 0.038 and p = 0.009, respectively). High-grade tumors displayed complex genomic profiles with multiple segmental losses including TP53, ATM and PTEN genes. The median genomic index was significantly higher in high grade than low grade tumors (27 [3–60] vs 5,3 [0–16], p < 0.0001) and was significantly higher in presence of SO in low grade tumors (12,8 [10–16] vs 2,6 [0–10], p = 0.0006). We propose to report sarcomatous overgrowth with the tumor grade for prognostication in adenosarcoma and representative sampling is crucial for evaluation of these histological criteria.

    langue originaleAnglais
    Pages (de - à)14-22
    Nombre de pages9
    journalHuman Pathology
    Volume148
    Les DOIs
    étatPublié - 1 juin 2024

    Contient cette citation